Ebola treatments trial begins in DR Congo

What This is

• A World Health Organization-backed clinical trial has started in eastern Democratic Republic of Congo to test potential treatments for the Bundibugyo strain of Ebola as the outbreak grows.
• The outbreak has exceeded about 1,400 confirmed cases and more than 400 deaths, and has spread beyond the initial area, including into Uganda.
• Health officials say response efforts are being slowed by insecurity, mistrust, and attacks on treatment centers, along with limits in beds, testing, and contact tracing.
• The United States is supplying MBP134 doses for compassionate use and trials and has begun efforts to identify vaccine candidates aimed at the Bundibugyo strain.
• Bundibugyo Ebola differs from the better-known Zaire strain, and there are no approved vaccines or treatments specifically for Bundibugyo.

Why This Matters

• Running a rigorous trial during conflict tests whether science can move fast in unstable settings.
• This outbreak highlights how gaps in vaccines, tests, and funding leave the world exposed to less-common Ebola strains.
• Better diagnostics and treatment access can help rebuild trust and improve people’s willingness to seek care early.
• Cross-border spread raises the stakes for regional cooperation and rapid support.